Evidence map›Paper›PMID 41706023›Full record

ArticleJournal of natural products2026

Gonystylones A-E, Antiproliferative 5,6-Dihydro-α-pyrones from the Plant

Chang-Kwon Kim, Vitor F Freire, Soumili Dey, Girma M Woldemichael, Yong Yean Kim, Xinyu Wen, Hsien-Chao Chou, Young K Song, Jun S Wei, Rhone K Akee and 5 more

Abstract read
In one paragraph

Article in Journal of natural products, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Chang-Kwon KimMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Vitor F FreireNatural Products Branch, Developmental Therapeutic Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702-1201, United States.ORCID 0000-0001-6565-1830
Soumili DeyOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States.
Girma M WoldemichaelBasic Science Program, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States.
Yong Yean KimOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States.
Xinyu WenOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States.
Hsien-Chao ChouOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States.
Young K SongOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States.
Jun S WeiOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States.
Rhone K AkeeNatural Products Support Group, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21702, United States.
Maria OrfanoudakiMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.ORCID 0000-0002-9409-7645
Masoumeh DalilianMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.
Javed KhanOncogenomics Section, Genetics Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, United States.
Tanja GrkovicMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.ORCID 0000-0002-6537-3997
Barry R O'KeefeMolecular Targets Program, Center for Cancer Research, National Cancer Institute, Frederick, Maryland 21702, United States.ORCID 0000-0003-0772-4856

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A high-throughput screening campaign designed to discover natural product inhibitors of rhabdomyosarcoma oncogene PAX3-FOXO1 gene expression identified partially purified fractions from an organic extract of the plant

Indexed as

Antineoplastic Agents, PhytogenicPyronesDrug Screening Assays, AntitumorHumansMolecular StructureNuclear Magnetic Resonance, BiomolecularRhabdomyosarcomaAntineoplastic Agents, PhytogenicPyrones

Identifiers

PMID41706023
PMCPMC12954756

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.